Evidence map›Paper›PMID 30806888›Full record

ArticleJournal of neuro-oncology2019

pH-weighted amine chemical exchange saturation transfer echoplanar imaging (CEST-EPI) as a potential early biomarker for bevacizumab failure in recurrent glioblastoma.

Jingwen Yao, Caleb Hock Pang Tan, Jacob Schlossman, Ararat Chakhoyan, Catalina Raymond, Whitney B Pope, Noriko Salamon, Albert Lai, Matthew Ji, Phioanh L Nghiemphu and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuro-oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 37 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Advanced MR Techniques for Preoperative Glioma Characterization: Part 2.Journal of magnetic resonance imaging : JMRI · 2023
    Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Jingwen YaoUCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, Los Angeles, CA, USA.
Caleb Hock Pang TanDepartment of Chemistry and Biochemistry, University of California Los Angeles, Los Angeles, CA, USA.
Jacob SchlossmanInterdepartmental Program for Neuroscience, University of California Los Angeles, Los Angeles, CA, USA.
Ararat ChakhoyanUCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, Los Angeles, CA, USA.
Catalina RaymondUCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, Los Angeles, CA, USA.
Whitney B PopeDepartment of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Noriko SalamonDepartment of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Albert LaiUCLA Neuro-Oncology Program, University of California, Los Angeles, Los Angeles, CA, USA.
Matthew JiUCLA Neuro-Oncology Program, University of California, Los Angeles, Los Angeles, CA, USA.
Phioanh L NghiemphuUCLA Neuro-Oncology Program, University of California, Los Angeles, Los Angeles, CA, USA.
Linda M LiauDepartment of Neurosurgery, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Timothy F CloughesyUCLA Neuro-Oncology Program, University of California, Los Angeles, Los Angeles, CA, USA.
Benjamin M EllingsonUCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California, Los Angeles, Los Angeles, CA, USA. bellingson@mednet.ucla.edu.ORCID http://orcid.org/0000-0002-2764-6640
University of California, Los Angeles · US

Funding

UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI David A. Nathanson · 2017 to 2026
$25.2M
Metabolic MRI for quantifying aerobic glycolysis and immune function in gliomasR21CA223757 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ELLINGSON, BENJAMIN M. · 2018 to 2019
$366k
American Cancer Society RSG-15-003-01-CCENational Cancer Institute 1P50CA211015-01A1National Cancer Institute 1R21CA223757-01NCI NIH HHS P50 CA211015NCI NIH HHS R21 CA223757
6 · The paper itself

Abstract

purposeThe objective of the current study was to explore the efficacy of using pH-weighted amine CEST-EPI as a potential non-invasive imaging biomarker for treatment response and/or failure in recurrent GBM patients treated with bevacizumab.

methodA total of 11 patients with recurrent GBM treated with bevacizumab were included in this prospective study. CEST-EPI, perfusion MRI, and standardized anatomic MRI were obtained in patients before and after bevacizumab administration. CEST-EPI measures of magnetization transfer ratio asymmetry (MTR

resultTumor acidity, measured with MTR

conclusionsThis pilot study suggests pH-weighted amine CEST MRI may have value as a non-invasive, early imaging biomarker for bevacizumab treatment response and failure. Early decreases MTR

Indexed as

AdultAgedAminesAntineoplastic Agents, ImmunologicalBevacizumabBiomarkersEcho-Planar ImagingFemaleFollow-Up StudiesGlioblastomaHumansHydrogen-Ion ConcentrationImage Processing, Computer-AssistedMagnetic Resonance ImagingMaleMiddle AgedAminesAntineoplastic Agents, ImmunologicalBevacizumabBiomarkersBevacizumabCESTGlioblastomapH-weighted imagingRecurrent GBM

Identifiers

PMID30806888
PMCPMC6482078
OpenAlexW2918089991

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.